CClinicalTrials.gg
Sign In
Status unknownNCT05334875Updated Apr 19, 2022

Repeatability of Electroretinogram and Visual Evoked Potential

An interventional study of Electroretinogram (ERG) and Visual evoked potential (VEP) in Retinal Disease, Visual Impairment and Vision Disorders, sponsored by Benha University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-19.

Sponsored by Benha University · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

To assess repeatability of electroretinogram and visual evoked potential in clinical practice

Read the detailed description

To assess repeatability of electroretinogram in evaluation of retinal function and visual evoked potential in evaluation of visual pathway in clinical practice.

02

Conditions studied

  • Retinal Disease
  • Visual Impairment
  • Vision Disorders

Keywords

  • Electroretinogram
  • Visual evoked potential
03

In context

Vision Disorders

308 studies on the registry are indexed under Vision Disorders; 81 are open to participants now.

This study's planned enrollment of 250 is above the median of 66 across 211 interventional studies indexed under Vision Disorders.

Browse Vision Disorders studies →

Lead sponsor

Benha University is the lead sponsor of 356 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Normal subjects visit banha university hospital seeking regular checkup and subjects asked for ERG and VEP as a pre-occupational examination.

Exclusion criteria

Exclusion Criteria:

  • Patients previously diagnosed with any retinal disease or visual pathway disease that may affect ERG and VEP tests.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Electroretinogram test (ERG)

    ERG test will be done for each subject twice and compare the results to assess repeatability of the test.

    Diagnostic Test: Electroretinogram (ERG)

  • Active comparator
    Visual evoked potential test (VEP)

    VEP test will be done for each subject twice and compare the results to assess repeatability of the test.

    Diagnostic Test: Visual evoked potential (VEP)

Interventions

  • Diagnostic testElectroretinogram (ERG)

    Applying electrodes to assess retinal function

  • Diagnostic testVisual evoked potential (VEP)

    Applying electrodes to assess visual pathway function

06

What researchers measure

Primary outcomes

  1. Repeatability of ERG amplitude.

    ERG amplitude measured in nano volt (nV).

    Time frame: Changes from baseline measurements and at one week.

Secondary outcomes

  1. Repeatability of ERG latency.

    Latency of ERG measured by millisecond (msec).

    Time frame: Changes from baseline measurements and at one week.

Other outcomes

  1. Repeatability of VEP amplitude.

    VEP amplitude measured in nano volt (nV).

    Time frame: Changes from baseline measurements and at one week.

  2. Repeatability of VEP latency.

    Latency of VEP measured by millisecond (msec).

    Time frame: Changes from baseline measurements and at one week.

07

Study locations

1 of 1 sites recruiting
  • Ahmed Abdelshafy Tabl
    Banhā, Benha 13511, Egypt
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05334875
Lead sponsor
Benha University
Responsible party
Ahmed Abdelshafy (Lecturer of Ophthalmology, Benha University) — Principal investigator
First posted
Apr 19, 2022
Start date
Apr 1, 2022
Primary completion
Oct 30, 2022 (estimated)
Completion
Oct 30, 2022 (estimated)
Last update
Apr 19, 2022

Study contacts

Ahmed Abdelshafy, MD
Contact
ahmad4lg@gmail.com
01222328766
Ahmed A Abdelshafy, MD
study chair · Benha University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Vision Disorders→

Other studies from this sponsor

Benha University

Start the discussion